---
title: -Oleoyl Glycerol is a GPR119 Agonist and Signals GLP-1 Release in Humans.
nct_id: NCT01043445
overall_status: COMPLETED
phase: NA
sponsor: Glostrup University Hospital, Copenhagen
study_type: INTERVENTIONAL
primary_condition: Type 2 Diabetes
countries: Denmark
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT01043445.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT01043445"
ct_last_update_post_date: 2014-10-09
last_seen_at: "2026-05-12T07:12:26.285Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# -Oleoyl Glycerol is a GPR119 Agonist and Signals GLP-1 Release in Humans.

**Official Title:** G Protein-coupled Receptor in the Intestine (GPR 119) Stimulated GLP-1 Secretion

**NCT ID:** [NCT01043445](https://clinicaltrials.gov/study/NCT01043445)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 8
- **Lead Sponsor:** Glostrup University Hospital, Copenhagen
- **Collaborators:** University of Copenhagen
- **Conditions:** Type 2 Diabetes
- **Start Date:** 2009-09
- **Completion Date:** 2010-04
- **CT.gov Last Update:** 2014-10-09

## Brief Summary

The purpose of this study is to evaluate the impact of different ligands of GPR 119 (a G protein-coupled receptor in the intestine) on the secretion of the incretin hormones, GLP-1 and GIP.

## Detailed Description

We have found a new ligand for the GPR 119 receptor. This study evaluate the impact of this ligand on the incretion hormone responses, beta cell function and gall bladder function in healthy young men.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 30 Years
- **Sex:** MALE
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* Healthy caucasians v- Normal OGTT (75 g of glucose) according to WHO's criteria
* Normal hemoglobin
* Informed consent

Exclusion Criteria:

* Liver disease (ALAT\> 2x normal level)
* Nephropathy (s-creatinin \>130 microM or albuminuria)
* Relatives with type 2 diabetes
```

## Arms

- **GPR119 agonist, 2-oleoyl glycerol** (EXPERIMENTAL) — 2-oleoyl glycerol; 2g. and vehicle
- **Oleic acid** (ACTIVE_COMPARATOR) — oleic acid; 3.2g and vehicle
- **Vehicle** (PLACEBO_COMPARATOR) — 5 ml. of glycerol and 5 ml 96% ethanol

## Interventions

- **GPR 119 agonist, 2-oleyl glycerol** (DIETARY_SUPPLEMENT) — Emulgation, 50 ml. containing 2g 2OG
- **Oleic acid** (DIETARY_SUPPLEMENT) — Emulgation, 50 ml. containing 1.54g of oleic acid
- **Vehicle** (DIETARY_SUPPLEMENT) — Fifty milliliters of glycerol (Sigma-Aldrich; batch 32296AK, purity 99%) plus 5 ml 96% ethanol

## Primary Outcomes

- **The effect of this newly discovered GPR 119 agonist on gut hormone responses, in particular GLP-1 in response of the different meals administered to the subjects** _(time frame: 1 year)_

## Secondary Outcomes

- **Glucose homeostasis, gall bladder contraction in response of the different meals administered to the subjects** _(time frame: 1 year)_

## Locations (1)

- Department of Clinical Physiology, Glostrup Hospital, Glostrup Municipality, Denmark

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.department of clinical physiology, glostrup hospital|glostrup municipality||denmark` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT01043445.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT01043445*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*